Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06696014 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mirikizumab Real World Protocol

Study acronym: MIRROR
StatusTerminated
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial terminated Sponsor's reason: Poor accrual Final enrollment: 6 participants — 6% of the 100 planned · Primary completion date changed from estimate of Jan 1, 2030 to Jul 8, 2026 · Eligibility criteria expanded, about 10 words · 3 more Show 6 more changesShow less
    • Final enrollment: 6 participants — 6% of the 100 planned
    • Primary completion date changed from estimate of Jan 1, 2030 to Jul 8, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Site details revised at 9 of 9 sites
    • Publications: details revised at 16 of 16 entries
  2. Study sites: 5 to 9v3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 5 · Start date changed from estimate of Dec 2, 2025 to May 8, 2025v2 Show 2 more changesShow less
    • Study sites: 1 to 5
    • Start date changed from estimate of Dec 2, 2025 to May 8, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.
Trial Details
NCT Number NCT06696014
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: Eli Lilly and Company
Conditions Ulcerative Colitis
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov